Page 37 - Read Online

Pellerino et al. J Cancer Metastasis Treat 2020;6:41 I http://dx.doi.org/10.20517/2394-4722.2020.80 Page 19 of 20

cell lung cancer. J Thorac Oncol 2013;8:1069-74.
99. Yang H, Yang X, Zhang Y, Liu X, Deng Q, et al. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and
cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib failure. Target Oncol 2015;10:135-40.
100. Kawamura T, Hata A, Takeshita J, Fujita S, Hayashi M, et al. High-dose erlotinib for refractory leptomeningeal metastases after failure of
standard-dose EGFR-TKIs. Cancer Chemother Pharmacol 2015;75:1261-6.
101. Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, et al. A phase I trial of high dose gefitinib for patients with leptomeningeal
metastases from non-small cell lung cancer. Oncotarget 2015;6:4527-36.
102. Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung
cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol 2015;10:1754-61.
103. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N
Engl J Med 2017;376:629-40.
104. Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive
non-small-cell lung cancer and leptomeningeal metastases: the bloom study. J Clin Oncol 2020;38:538-47.
105. Saboundji K, Auliac JB, Perol M, François G, Janicot H, et al. Efficacy of osimertinib in EGFR mutated non-small-cell lung cancer with
leptomeningeal metastases pretreated with EGFR tyrosine kinase inhibitors. Target Oncol 2018;13:501-7.
106. Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, et al. Osimertinib for patients with leptomeningeal metastases associated with EGFR
T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis. J Thorac Oncol 2020;15:637-48.
107. Park S, Lee MH, Seong M, Kim ST, Cho BC, et al. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-
positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Ann Oncol 2020;S0923-7534(20)39927-0.
108. Okuno T, Arakawa S, Yoshida T, Ohe Y. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I
mutation. Lung Cancer 2020;143:95-6.
109. Ahn MJ, Kim DW, Kim TM, Lin CC, Ratnayake J, et al. Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment
of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM). J Clin Oncol 2016;9003.
110. Cho BC, Ahn M, Lee J, Kim DW, Kim SW, et al. Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm
NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anticancer therapy. J Clin Oncol 2017;2069 (abstr).
111. Macias A, Neninger E, Santiesteban E, Boland W, Nicacio L, et al. 505 POSTER preliminary results of a phase II clinical trial of the anti
EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-
small cell lung cancer tumors unresectable brain metastases. Eur J Cancer Suppl 2008;6:160-1.
112. Xu H, Zhou L, Lu Y, Su X, Cheng P, et al. Dual targeting of the epidermal growth factor receptor using combination of nimotuzumab
and erlotinib in advanced non-small-cell lung cancer with leptomeningeal metastases: a report of three cases. Onco Targets Ther
2020;13:647-56.
113. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged
non-small-cell lung cancer and brain metastases J Clin Oncol 2015;33:1881-8.
114. Ahn HK, Han B, Lee SJ, Lim T, Sun SM, et al. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small
cell lung cancer with leptomeningeal carcinomatosis. Lung Cancer 2012;76:253-4.
115. Crinò L, Ahn MJ, De Marinis F, Groen HJM, Wakelee H, et al. Multicenter phase II study of whole-body and intracranial activity with
ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from
ASCEND-2. J Clin Oncol 2016;34:2866-73.
116. Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell
lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet
Oncol 2017;18:874-86.
117. Arrondeau J, Ammari S, Besse B, Soria JC. LDK378 compassionate use for treating carcinomatous meningitis in an ALK translocated
non-small-cell lung cancer. J Thorac Oncol 2014;9:e62-3.
118. Dudnik E, Siegal T, Zach L, Allen AM, Flex D, et al. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive
non-small cell lung cancer compared with brain radiotherapy. J Clin Neurosci 2016;26:46-9.
119. Chow LQ, Barlesi F, Bertino EM, Branle F, Shi M, et al. Results of the ASCEND-7 phase II study evaluating ALK inhibitor ceritinib in
patients with ALK+ non-small cell lung cancer metastatic to the brain. ESMO Congress 2019. Abstract 1478O. Available from: https://
www.annalsofoncology.org/article/S0923-7534(19)59686-7/fulltext. [Last accessed on 22 Oct 2020]
120. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung
cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017;390:29-39.
121. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung
cancer. N Engl J Med 2017;377:829-38.
122. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients
previously treated with crizotinib and ceritinib. J Thorac Oncol 2015;10:232-6.
123. Ou SH, Sommers KR, Azada MC, Garon EB. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small
cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 2015;20:224-6.
124. Gainor JF, Chi AS, Logan J, Hu RL, Oh KS, et al. Alectinib dose escalation reinduces central nervous system responses in patients with
anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol 2016;11:256-60.
125. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell